{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:49:29Z","timestamp":1791866969609,"version":"4.3.4"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Innate and adaptive immune cell dysregulation contributes to ulcerative colitis pathogenesis. The sphingosine 1-phosphate receptor modulator etrasimod showed efficacy in ulcerative colitis treatment in Phase 3 ELEVATE UC studies. Changes in circulating immune cells and mucosal cell types were characterized in etrasimod-treated patients with ulcerative colitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Blood (etrasimod n\u2009=\u2009525, placebo n\u2009=\u2009257 patients) and mucosal biopsies (etrasimod n\u2009=\u2009411, placebo n\u2009=\u2009200 patients) from patients in the ELEVATE UC trials were used to assess cellular and molecular changes for etrasimod versus placebo in clinical remitters and non-remitters using immunophenotyping, transcriptomic and proteomic techniques.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Selective and partial reduction in circulating T- and B-cell subsets was observed for etrasimod versus placebo (Week 12), with greater effects on CD4+ T cells, including Treg and Th17 cells, than CD8+ T cells, and on naive T cells and T central memory cells than T effector memory cells, without difference between remitters and non-remitters. No significant effects on monocytes nor NK cell numbers were observed. Mucosal biopsies showed corresponding reductions in T- and B-cell subsets, myeloid cells and neutrophils accompanied by downregulation of interleukin-17 and interleukin-8 signaling in both tissue and blood, most prominently in remitters, where non-immune cell changes were consistent with tissue repair.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Etrasimod treatment of patients with ulcerative colitis drives T- and B-lymphocyte subset reductions in blood and intestinal mucosa, neutrophil reductions in tissue and mucosal downregulation of inflammatory pathways associated with ulcerative colitis pathogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trials registration number<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (NCT03945188; NCT03996369).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag159","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:51:09Z","timestamp":1790164269000},"source":"Crossref","is-referenced-by-count":0,"title":["Etrasimod reduces circulating and mucosal inflammatory lymphocyte populations and alters innate immune and non-immune cell signatures in intestinal mucosa: ELEVATE UC phase 3 clinical data"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-958X","authenticated-orcid":false,"given":"Britta","family":"Siegmund","sequence":"first","affiliation":[{"name":"Med. Klinik f\u00fcr Gastroenterologie, Infektiologie, Rheumatologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M","family":"Crosby","sequence":"additional","affiliation":[{"name":"Formerly of Pfizer Inc., La Jolla , San Diego, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rathi D","family":"Ryan","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , South San Francisco, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Smith","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Groton, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T","family":"Abreu","sequence":"additional","affiliation":[{"name":"F. Widjaja Inflammatory Bowel Disease Institute, Cedars-Sinai , Los Angeles, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah Tikva,","place":["Israel"]},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren M","family":"Rabinowitz","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah Tikva,","place":["Israel"]},{"name":"Felsentstein Medical Research Centre, Medical and Health Sciences , Tel Aviv,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Kiyomi","family":"Komori","sequence":"additional","affiliation":[{"name":"Formerly of Arena Pharmaceuticals, San Diego, CA, United States; a wholly-owned subsidiary of Pfizer Inc. , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Goetsch","sequence":"additional","affiliation":[{"name":"Pfizer AG , Z\u00fcrich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7233-0933","authenticated-orcid":false,"given":"Karolina","family":"Wosik","sequence":"additional","affiliation":[{"name":"Pfizer Canada , Kirkland, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Woolcott","sequence":"additional","affiliation":[{"name":"Formerly of Pfizer Inc. , Collegeville, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita Salute San Raffaele University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"2026101300431855500_jjag159-B1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026101300431855500_jjag159-B2","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2026101300431855500_jjag159-B3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jbior.2016.11.001","article-title":"Sphingolipids in neutrophil function and inflammatory responses: mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis","volume":"63","author":"Espaillat","year":"2017","journal-title":"Adv Biol Regul"},{"key":"2026101300431855500_jjag159-B4","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1097\/MIB.0000000000000203","article-title":"Naive T cells in the gut of newly diagnosed, untreated adult patients with inflammatory bowel disease","volume":"20","author":"Horjus Talabur Horje","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026101300431855500_jjag159-B5","doi-asserted-by":"crossref","first-page":"eabb4432","DOI":"10.1126\/sciimmunol.abb4432","article-title":"Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses","volume":"5","author":"Boland","year":"2020","journal-title":"Sci Immunol"},{"key":"2026101300431855500_jjag159-B6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/ecco-jcc\/jjx160","article-title":"Intestinal T cell profiling in inflammatory bowel disease: linking T cell subsets to disease activity and disease course","volume":"12","author":"Smids","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026101300431855500_jjag159-B7","doi-asserted-by":"crossref","first-page":"i314","DOI":"10.1093\/ecco-jcc\/jjad212.0182","article-title":"P052 Mucosal IgG-like naive B-cell expansion and maturation contribute to ulcerative colitis pathogenesis","volume":"18","author":"Fung","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026101300431855500_jjag159-B8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3390\/jcm11020400","article-title":"The role of innate and adaptive immune cells in the pathogenesis and development of the inflammatory response in ulcerative colitis","volume":"11","author":"Kaluzna","year":"2022","journal-title":"J Clin Med"},{"key":"2026101300431855500_jjag159-B9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nri2653","article-title":"Intestinal mucosal barrier function in health and disease","volume":"9","author":"Turner","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2026101300431855500_jjag159-B10","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"2026101300431855500_jjag159-B11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cgh.2024.07.010","article-title":"Endoscopic, histologic, and composite endpoints in patients with ulcerative colitis treated with etrasimod","volume":"23","author":"Magro","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026101300431855500_jjag159-B12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/mi.2016.35","article-title":"Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease","volume":"10","author":"Karuppuchamy","year":"2017","journal-title":"Mucosal Immunol"},{"key":"2026101300431855500_jjag159-B13","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1194\/jlr.R046300","article-title":"An update on the biology of sphingosine 1-phosphate receptors","volume":"55","author":"Blaho","year":"2014","journal-title":"J Lipid Res"},{"key":"2026101300431855500_jjag159-B14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"2026101300431855500_jjag159-B15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1172\/JCI12450","article-title":"Sphingosine 1-phosphate promotes endothelial cell barrier integrity by EDG-dependent cytoskeletal rearrangement","volume":"108","author":"Garcia","year":"2001","journal-title":"J Clin Invest"},{"key":"2026101300431855500_jjag159-B16","doi-asserted-by":"crossref","first-page":"1427509","DOI":"10.3389\/fimmu.2024.1427509","article-title":"Sphingosine-1-phosphate receptor 4 links neutrophils and early local inflammation to lymphocyte recruitment into the draining lymph node to facilitate robust germinal center formation","volume":"15","author":"Luker","year":"2024","journal-title":"Front Immunol"},{"key":"2026101300431855500_jjag159-B17","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1096\/fj.10-179028","article-title":"Sphingosine-1-phospate receptor 4 (S1P4) deficiency profoundly affects dendritic cell function and TH17-cell differentiation in a murine model","volume":"25","author":"Schulze","year":"2011","journal-title":"FASEB J"},{"key":"2026101300431855500_jjag159-B18","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/ni1523","article-title":"Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor","volume":"8","author":"Walzer","year":"2007","journal-title":"Nat Immunol"},{"key":"2026101300431855500_jjag159-B19","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1158\/1538-7445.AM2024-2659","article-title":"Abstract 2659: Therapeutic administration of an engineered sphingosine-1-phosphate lyase improves T cell trafficking to tumors and enhances antitumor response","volume":"84","author":"Araujo","year":"2024","journal-title":"Cancer Res"},{"key":"2026101300431855500_jjag159-B20","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"2026101300431855500_jjag159-B21","author":"Precision Epiontis ID: Epiontis ID\u00ae. Presicion Medicine Group","year":"2025"},{"key":"2026101300431855500_jjag159-B22","author":"Olink Target 96 Inflammation Panels: Olink\u00ae","year":"2024"},{"key":"2026101300431855500_jjag159-B23","doi-asserted-by":"crossref","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"2026101300431855500_jjag159-B24","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"voom: Precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol"},{"key":"2026101300431855500_jjag159-B25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"2026101300431855500_jjag159-B26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1124\/jpet.118.254268","article-title":"The selective sphingosine 1-phosphate receptor modulator etrasimod regulates lymphocyte trafficking and alleviates experimental colitis","volume":"369","author":"Al-Shamma","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"2026101300431855500_jjag159-B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.04933","article-title":"Etrasimod, a selective S1P1,4,5 receptor modulator, exhibits differential G protein signaling compared to other S1P receptor modulators","volume":"34","author":"Komori","year":"2020","journal-title":"FASEB J"},{"key":"2026101300431855500_jjag159-B28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cpdd.1379","article-title":"Safety, pharmacokinetics, and pharmacodynamics of etrasimod: single and multiple ascending dose studies in healthy adults","volume":"13","author":"Lee","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026101300431855500_jjag159-B29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"2026101300431855500_jjag159-B30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41531-024-00652-y","article-title":"Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson\u2019s disease patients","volume":"10","author":"Weber","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"2026101300431855500_jjag159-B31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.leu.2403704","article-title":"CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets","volume":"19","author":"Penack","year":"2005","journal-title":"Leukemia"},{"key":"2026101300431855500_jjag159-B32","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/ecco-jcc\/jjae060","article-title":"Etrasimod for the treatment of ulcerative colitis: analysis of infection events from the ELEVATE UC clinical programme","volume":"18","author":"Regueiro","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026101300431855500_jjag159-B33","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1212\/NXI.0000000000000839","article-title":"Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS","volume":"7","author":"Harris","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026101300431855500_jjag159-B34","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1007\/s10620-024-08391-z","article-title":"Ozanimod differentially impacts circulating lymphocyte subsets in patients with moderately to severely active Crohn\u2019s disease","volume":"69","author":"Harris","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2026101300431855500_jjag159-B35","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/gut.38.1.90","article-title":"Interleukin 8: cells of origin in inflammatory bowel disease","volume":"38","author":"Grimm","year":"1996","journal-title":"Gut"},{"key":"2026101300431855500_jjag159-B36","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180984","article-title":"Advancing chemokine research: the molecular function of CXCL8","volume":"134","author":"Hou","year":"2024","journal-title":"J Clin Invest"},{"key":"2026101300431855500_jjag159-B37","doi-asserted-by":"crossref","first-page":"1001025","DOI":"10.3389\/fimmu.2022.1001025","article-title":"From bench to bedside: calprotectin (S100A8\/S100A9) as a biomarker in rheumatoid arthritis","volume":"13","author":"Inciarte-Mundo","year":"2022","journal-title":"Front Immunol"},{"key":"2026101300431855500_jjag159-B38","first-page":"997","article-title":"Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation","volume":"144","author":"Mazzucchelli","year":"1994","journal-title":"Am J Pathol"},{"key":"2026101300431855500_jjag159-B39","doi-asserted-by":"crossref","first-page":"i1579","DOI":"10.1093\/ecco-jcc\/jjae190.1002","article-title":"P0828 The impact of etrasimod on neutrophils in the ELEVATE UC clinical programme","volume":"19","author":"Allez","year":"2025","journal-title":"J Crohn\u2019s Col"},{"key":"2026101300431855500_jjag159-B40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"2026101300431855500_jjag159-B41","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1097\/MIB.0b013e3182a85709","article-title":"Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients","volume":"19","author":"Ueno","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2026101300431855500_jjag159-B42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood-2009-04-216085","article-title":"Evidence for a cross-talk between human neutrophils and Th17 cells","volume":"115","author":"Pelletier","year":"2010","journal-title":"Blood"},{"key":"2026101300431855500_jjag159-B43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2026101300431855500_jjag159-B44","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/17474124.2022.2100759","article-title":"Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis","volume":"16","author":"Bamias","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2026101300431855500_jjag159-B45","first-page":"53","article-title":"The use of fecal calprotectin in inflammatory bowel disease","volume":"13","author":"Bjarnason","year":"2017","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2026101300431855500_jjag159-B46","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ibd\/izae111","article-title":"The effect of etrasimod on fecal calprotectin and high-sensitivity C-reactive protein: results from the ELEVATE UC clinical program","volume":"31","author":"Jairath","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026101300431855500_jjag159-B47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.intimp.2017.08.012","article-title":"CCL28 chemokine: an anchoring point bridging innate and adaptive immunity","volume":"51","author":"Mohan","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"2026101300431855500_jjag159-B48","doi-asserted-by":"crossref","first-page":"44645","DOI":"10.1074\/jbc.M112.423426","article-title":"Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1","volume":"287","author":"Wilkerson","year":"2012","journal-title":"J Biol Chem"},{"key":"2026101300431855500_jjag159-B49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.trsl.2021.06.001","article-title":"Epithelial wound healing in inflammatory bowel diseases: the next therapeutic frontier","volume":"236","author":"Liu","year":"2021","journal-title":"Transl Res"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/10\/jjag159\/71889387\/jjag159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/10\/jjag159\/71889387\/jjag159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:43:52Z","timestamp":1791866632000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag159\/8911624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag159","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10]]},"article-number":"jjag159"}}